TORONTO, Sept. 18, 2014 /CNW/ - Microbix Biosystems Inc. (TSX: MBX), an innovator and manufacturer of biological products and technologies, has been named a finalist for the prestigious Ontario Business Achievement Award (OBAA) sponsored by the Ontario Chamber of Commerce in the Ontario Going Global medium-sized business category. This award honours companies in Canada's most populous province with 50-500 employees that have increased exports by 20% or more in one year. This year, Microbix is one of two finalists selected from over 100 businesses considered for the Ontario Going Global award.
"I believe Microbix exemplifies Ontario's ideal of a fast growing mid-sized company," says Vaughn Embro-Pantalony, President and CEO of Microbix. "Consider that we are a high-tech life sciences company; we employ a diverse and highly skilled team of scientists and technologists; we have expanded our workforce nearly 50% in the last 12 months; we are developing innovative products including our new dengue fever antigens and molecular diagnostics products; and we have grown our export sales more than 35% in the past year."
The Ontario Chamber of Commerce, host of the "OBAAs", will announce the Ontario Going Global winners at a gala event in Toronto in November.
"Being recognized by the Ontario Chamber of Commerce for our success is an important endorsement of our recent accomplishments at Microbix." says Mr. Embro-Pantalony.
The OBAAs have been honouring Ontario's most successful businesses and celebrating their impact on the provincial economy annually for 32 years. This year again they will recognize the integrity, hard work, innovation, entrepreneurship, and export excellence that goes into making good companies great. The 2014 OBAAs gala runs from 6:00 to 9:30 p.m. on Wednesday, November 26 at the Metro Toronto Convention Centre. To reserve tickets [explain how or provide a link].
About Microbix Biosystems Inc.
Microbix Biosystems Inc. specializes in the research and development of biological solutions, including products for human health applications, namely in the vaccine, therapeutic and diagnostic markets, as well as animal reproductive markets worldwide. The Company manufactures and distributes a wide range of infectious disease antigens to a worldwide customer base. The Company's pipeline of innovative technologies and products includes LumiSort™ semen sexing technology for the livestock industries, Kinlytic®, a thrombolytic drug with several approved and potential applications including the treatment of life-threatening blood clots, and VIRUSMAX®, a proprietary technology for increasing virus yields in the manufacture of influenza vaccine. Established in 1988, Microbix is a publicly traded company, listed on the Toronto Stock Exchange, and headquartered in Mississauga, Ontario.
This press release may contain forward-looking statements which are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements. These forward-looking statements represent the Company's judgment as of the date of this press release. The Company disclaims any intent or obligation to update these forward-looking statements
SOURCE: Microbix Biosystems Inc.
For further information: Visit www.microbix.com or contact: Vaughn Embro-Pantalony, President and CEO, (905) 361-8910 x 350; or Charles Wallace, CFO, (905) 361-8910 x 255.